Price T Rowe Associates Inc Biotechnology

Price T Rowe Associates Inc

$812 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ARGX Argenx Se	$32.5B	$3.19 Billion 0.39% of portfolio	5,384,586	Q1 2025 Reduced 2.4%
VRTX Vertex Pharmaceuticals Inc	$112B	$1.41 Billion 0.17% of portfolio	2,917,227	Q1 2025 Added 72.55%
REGN Regeneron Pharmaceuticals, Inc.	$63.1B	$1.38 Billion 0.17% of portfolio	2,175,026	Q1 2025 Added 4.3%
INSM Insmed Inc	$9.15B	$986 Million 0.12% of portfolio	12,923,541	Q1 2025 Added 1.72%
ALNY Alnylam Pharmaceuticals, Inc.	$35.7B	$946 Million 0.12% of portfolio	3,505,168	Q1 2025 Added 5.6%
BGNE Bei Gene, Ltd.	$23.5B	$739 Million 0.09% of portfolio	2,713,418	Q1 2025 Reduced 7.62%
TECH Bio Techne Corp	$1.83B	$667 Million 0.08% of portfolio	11,375,279	Q1 2025 Added 6.77%
BPMC Blueprint Medicines Corp	$6.06B	$479 Million 0.06% of portfolio	5,415,837	Q1 2025 Reduced 4.64%
NVO Novo Nordisk A S	$152B	$370 Million 0.05% of portfolio	5,324,666	Q1 2025 Reduced 16.08%
ASND Ascendis Pharma A/S	$9.04B	$352 Million 0.04% of portfolio	2,256,102	Q1 2025 Reduced 1.19%
RNA Avidity Biosciences, Inc.	$1.59B	$335 Million 0.04% of portfolio	11,338,098	Q1 2025 Added 2.67%
SRRK Scholar Rock Holding Corp	$1.55B	$286 Million 0.04% of portfolio	8,893,886	Q1 2025 Reduced 4.2%
LEGN Legend Biotech Corp	$4.84B	$228 Million 0.03% of portfolio	6,729,779	Q1 2025 Reduced 1.15%
RVMD Revolution Medicines, Inc.	$3.49B	$198 Million 0.02% of portfolio	5,599,642	Q1 2025 Reduced 4.54%
AKRO Akero Therapeutics, Inc.	$2.15B	$195 Million 0.02% of portfolio	4,817,091	Q1 2025 Added 11.46%
KYMR Kymera Therapeutics, Inc.	$1.61B	$183 Million 0.02% of portfolio	6,702,450	Q1 2025 Reduced 2.44%
MDGL Madrigal Pharmaceuticals, Inc.	$4.58B	$180 Million 0.02% of portfolio	542,633	Q1 2025 Reduced 7.84%
CRNX Crinetics Pharmaceuticals, Inc.	$1.6B	$171 Million 0.02% of portfolio	5,112,360	Q1 2025 Reduced 5.58%
PCVX Vaxcyte, Inc.	$1.93B	$134 Million 0.02% of portfolio	3,542,007	Q1 2025 Reduced 10.71%
SMMT Summit Therapeutics Inc.	$5.2B	$127 Million 0.02% of portfolio	6,557,804	Q1 2025 Reduced -0.0%
ACLX Arcellx, Inc.	$2.8B	$121 Million 0.01% of portfolio	1,839,624	Q1 2025 Reduced 13.28%
VRNA Verona Pharma PLC	$4.58B	$118 Million 0.01% of portfolio	1,866,280	Q1 2025 Added 1.79%
RARE Ultragenyx Pharmaceutical Inc.	$2.5B	$117 Million 0.01% of portfolio	3,218,942	Q1 2025 Added 28.12%
MLTX Moon Lake Immunotherapeutics	$1.44B	$116 Million 0.01% of portfolio	2,973,830	Q1 2025 Reduced 11.06%
VERA Vera Therapeutics, Inc.	$531M	$114 Million 0.01% of portfolio	4,754,832	Q1 2025 Added 8.63%
SWTX Spring Works Therapeutics, Inc.	$2.9B	$114 Million 0.01% of portfolio	2,582,732	Q1 2025 Reduced 21.13%
REPL Replimune Group, Inc.	$412M	$106 Million 0.01% of portfolio	10,853,832	Q1 2025 Reduced 0.99%
NUVL Nuvalent, Inc.	$3.16B	$103 Million 0.01% of portfolio	1,450,602	Q1 2025 Added 11.76%
IONS Ionis Pharmaceuticals Inc	$4.68B	$98.5 Million 0.01% of portfolio	3,265,034	Q1 2025 Reduced 14.68%
ZLAB Zai Lab LTD	$3.07B	$82 Million 0.01% of portfolio	2,268,216	Q1 2025 Reduced 3.65%
CYTK Cytokinetics Inc	$2.88B	$80.1 Million 0.01% of portfolio	1,993,896	Q1 2025 Reduced 24.04%
CNTA Centessa Pharmaceuticals PLC	$1.21B	$76.8 Million 0.01% of portfolio	5,342,344	Q1 2025 Reduced 0.41%
HALO Halozyme Therapeutics, Inc.	$7.6B	$75.7 Million 0.01% of portfolio	1,186,730	Q1 2025 Reduced 2.59%
KRYS Krystal Biotech, Inc.	$3.21B	$74.1 Million 0.01% of portfolio	410,861	Q1 2025 Reduced 19.35%
AGIO Agios Pharmaceuticals, Inc.	$1.63B	$67.4 Million 0.01% of portfolio	2,301,353	Q1 2025 Reduced 5.04%
PTGX Protagonist Therapeutics, Inc	$2.24B	$63.9 Million 0.01% of portfolio	1,322,006	Q1 2025 Reduced 5.07%
MIRM Mirum Pharmaceuticals, Inc.	$1.62B	$63.8 Million 0.01% of portfolio	1,415,137	Q1 2025 Reduced 0.53%
RYTM Rhythm Pharmaceuticals, Inc.	$3.47B	$63.5 Million 0.01% of portfolio	1,199,053	Q1 2025 Added 75.01%
CLDX Celldex Therapeutics, Inc.	$952M	$61.9 Million 0.01% of portfolio	3,410,499	Q1 2025 Reduced 4.12%
EXEL Exelixis, Inc.	$13.6B	$59.8 Million 0.01% of portfolio	1,618,518	Q1 2025 Reduced 8.39%
DNLI Denali Therapeutics Inc.	$1.8B	$59.4 Million 0.01% of portfolio	4,367,234	Q1 2025 Added 42.78%
BEAM Beam Therapeutics Inc.	$1.18B	$59.1 Million 0.01% of portfolio	3,026,701	Q1 2025 Added 72.64%
UTHR United Therapeutics Corp	$14B	$58.5 Million 0.01% of portfolio	189,731	Q1 2025 Reduced 52.31%
IDYA Ideaya Biosciences, Inc.	$905M	$56.9 Million 0.01% of portfolio	3,475,622	Q1 2025 Reduced 10.12%
IMCR Immunocore Holdings PLC	$1.37B	$56 Million 0.01% of portfolio	1,887,940	Q1 2025 Reduced 13.7%
MRUS Merus N.V.	$2.53B	$46.1 Million 0.01% of portfolio	1,095,742	Q1 2025 Reduced 1.89%
PRTA Prothena Corp Public LTD CO	$309M	$42.8 Million 0.01% of portfolio	3,455,856	Q1 2025 Reduced 6.24%
ADMA Adma Biologics, Inc.	$4.01B	$41.9 Million 0.01% of portfolio	2,110,931	Q1 2025 Added 0.49%
XNCR Xencor Inc	$452M	$41.8 Million 0.01% of portfolio	3,930,647	Q1 2025 Reduced 2.62%
BBIO Bridge Bio Pharma, Inc.	$4.94B	$40.3 Million 0.0% of portfolio	1,164,967	Q1 2025 Added 17.53%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.